Attention Deficit Hyperactivity Disorder (ADHD) Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Stimulant, Non-stimulant), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies), by region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAttention Deficit Hyperactivity Disorder (ADHD) Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Stimulant, Non-stimulant), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies), by region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2022) | 15.30 billion |
| CAGR (2023-2028) | 4.10% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Market Overview
Global Attention Deficit Hyperactivity Disorder (ADHD) Market has valued at USD 15.30 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.10% through 2028. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that primarily affects children but can persist into adolescence and adulthood. It is characterized by a combination of persistent and impairing symptoms related to attention, hyperactivity, and impulsivity. ADHD can significantly impact an individual's daily functioning, including their academic performance, relationships, and overall quality of life. Individuals with ADHD often struggle with sustained attention and focus. They may have difficulty organizing tasks, following instructions, and completing assignments or chores. Common signs of inattention include forgetfulness, distractibility, and frequent careless mistakes in school or work. Hyperactivity in ADHD refers to excessive and inappropriate levels of physical restlessness or activity. In children, this may manifest as difficulty sitting still, running, or climbing excessively, or talking excessively. In adults, it may manifest as inner restlessness and a sense of being constantly "on the go." Impulsivity involves acting without thinking through the consequences. Individuals with ADHD may blurt out answers before questions are completed, interrupt others in conversations, and have difficulty waiting their turn. Impulsive behavior can lead to social and academic difficulties.
The rising incidence of ADHD, particularly among children and adolescents, has been a significant driver. As more individuals are diagnosed with ADHD, there is a growing demand for ADHD treatments. Efforts to increase awareness about ADHD, its symptoms, and found at treatments have led to more individuals seeking diagnosis and treatment. Increased awareness can drive market growth. Improved diagnostic tools and methods have made it easier to identify ADHD in patients. Timely and accurate diagnosis is a critical factor in driving the demand for ADHD treatments. Pharmaceutical companies are continually researching and developing new ADHD medications with improved efficacy, safety, and convenience. The introduction of novel drugs can stimulate market growth. The COVID-19 pandemic accelerated the adoption of telehealth services, including for ADHD diagnosis and treatment. Telehealth can improve access to care and drive market growth.
Key Market Drivers
Advancements in Diagnosis
The most widely used diagnostic criteria for ADHD are outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10 and ICD-11). These criteria provide standardized guidelines for diagnosing ADHD, ensuring consistency in diagnosis. Various objective assessment tools have been developed to aid in the diagnosis of ADHD. One of the most common tools is the ADHD Rating Scale, which involves a structured interview and assessment of ADHD symptoms. Other tools, such as the Conners' Rating Scales and Vanderbilt Assessment Scales, are also frequently used. Computerized neuropsychological tests and continuous performance tests (CPTs) have been developed to assess attention, impulsivity, and executive functioning. These tests provide objective data that can assist in diagnosis. Direct observation of a person's behavior, often in a classroom or clinical setting, can be a valuable diagnostic tool. Teachers, parents, and caregivers may provide input on the individual's behavior, which is considered alongside other assessment methods. While not a primary diagnostic tool, neuroimaging techniques like functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have provided insights into the neurological basis of ADHD. These tools can aid in research and further our understanding of the condition.
Advances in genetics and biomarker research have suggested that ADHD may have a genetic component. Although not currently used for diagnosis, ongoing research in this area may lead to the identification of genetic markers that can aid in diagnosis. Self-report scales and questionnaires, such as the Adult ADHD Self-Report Scale (ASRS), can be valuable in assessing symptoms and behaviors in adults. These tools help individuals provide information about their own experiences. A thorough developmental history, including information about early childhood behaviors and milestones, is an essential part of the diagnostic process. This history helps healthcare professionals understand the long-term pattern of ADHD symptoms. A comprehensive diagnosis often involves a multimodal assessment, incorporating information from multiple sources, including parents, teachers, caregivers, and the individual being evaluated. This holistic approach helps ensure a more accurate diagnosis. Advancements in diagnosis also recognize the importance of considering cultural factors and variations in symptom presentation. ADHD may manifest differently in individuals from diverse cultural backgrounds. This factor will help in the development of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.
Development of New Medications
While stimulant medications have traditionally been the primary treatment for ADHD, there is growing interest in non-stimulant alternatives. Non-stimulant medications, such as atomoxetine (Strattera) and guanfacine (Intuniv), have been developed and approved for the treatment of ADHD. These medications work through different mechanisms and may be preferred in cases where stimulants are not suitable due to side effects or patient preferences. Extended-release formulations of ADHD medications are designed to provide symptom control throughout the day, reducing the need for multiple doses. These formulations improve convenience and compliance. For example, long-acting methylphenidate and amphetamine products are found at. Prodrugs are compounds that are converted into active medications within the body. Some pharmaceutical companies are developing prodrug formulations of ADHD medications to enhance efficacy, reduce side effects, and improve the duration of action. Advances in drug delivery technology have led to the development of innovative delivery systems for ADHD medications. These include transdermal patches and controlled-release formulations that release the medication gradually over time. Researchers are exploring alternative mechanisms of action to target ADHD symptoms. For example, certain medications are designed to modulate neurotransmitters other than dopamine and norepinephrine, such as glutamate or histamine receptors.
Some pharmaceutical companies are investigating combination therapies, where two or more medications with different mechanisms of action are combined to enhance efficacy and address multiple aspects of ADHD symptoms. There is a growing interest in non-prescription and dietary supplement options for ADHD management. While these products are not medications, some individuals use them as complementary or alternative treatments. Patient-centered care is becoming increasingly important in ADHD treatment. Medications that offer flexibility in dosing, fewer side effects, and better tolerability are prioritized to align with individual patient preferences and needs. Advances in genetics and biomarker research may lead to the identification of specific markers or genetic factors that can help tailor medication choices to individual patients. The development of ADHD medications includes efforts to improve safety profiles, minimize side effects, and reduce the potential for misuse or abuse, particularly in the case of stimulant medications. Researchers are conducting long-term studies to better understand the effects of ADHD medications in the long run, particularly into adulthood, as ADHD is a lifelong condition. This factor will pace up the demand of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.
Increasing Prevalence of ADHD
Greater awareness and understanding of ADHD among healthcare professionals, educators, parents, and the public have led to increased recognition of the condition. As people become more knowledgeable about ADHD, they are more likely to seek help and diagnosis. Advances in diagnostic criteria and assessment tools have made it easier to identify ADHD in individuals. Healthcare providers now have more accurate and standardized methods for diagnosing the condition. Efforts to reduce the stigma surrounding mental health conditions, including ADHD, have encouraged individuals and families to seek help without fear of judgment. This has contributed to higher diagnosis rates. Early intervention is essential in managing ADHD effectively. As awareness grows, more children are being diagnosed and receiving appropriate interventions, which can lead to better outcomes. While ADHD is often associated with children, there is also a growing recognition of ADHD in adolescents and adults. This expanded age range has increased the overall prevalence of ADHD diagnoses. Some environmental factors, such as exposure to certain toxins or prenatal factors, have been studied in relation to ADHD. While the exact causes of ADHD are not fully understood, research into these factors may contribute to an increased understanding of the condition. Research suggests that genetics play a role in the development of ADHD. As genetic studies advance, it may become easier to identify individuals at risk and diagnose the condition. ADHD is recognized as a global condition, and its prevalence is not limited to any specific region or country. As globalization continues, the prevalence of ADHD is likely to increase in different parts of the world. This factor will accelerate the demand of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.
Key Market Challenges
Stigma and Awareness
Stigma often arises from misconceptions and stereotypes about ADHD. Some people believe that ADHD is not a real medical condition or that it is simply a result of laziness or poor parenting. This can lead to individuals with ADHD facing discrimination or judgment. Stigma can deter individuals and their families from seeking help for ADHD. They may fear being labeled, misunderstood, or stigmatized by others, which can delay diagnosis and treatment. Stigmatization can negatively affect the self-esteem and self-worth of individuals with ADHD. They may internalize negative beliefs about themselves, which can hinder their personal and academic development. Lack of awareness about ADHD can lead to late or missed diagnoses, particularly in adults. Many individuals may not recognize their symptoms as signs of ADHD, and healthcare providers may not consider it as a potential diagnosis. Limited awareness can contribute to both underdiagnosis and overdiagnosis of ADHD. Some individuals with ADHD may go undiagnosed, while others may be misdiagnosed due to a lack of understanding about the condition. Stigmatization can lead to social isolation for individuals with ADHD, as they may be excluded or bullied by peers. This isolation can have long-term psychological and emotional consequences.
Side Effects and Tolerance
Many medications used to treat ADHD, particularly stimulant medications like methylphenidate and amphetamines, can cause side effects. Common side effects may include insomnia, decreased appetite, weight loss, increased heart rate, and nervousness. Side effects can significantly impact an individual's quality of life, especially when they are bothersome or severe. For example, sleep disturbances can affect daily functioning and well-being. Side effects may lead to poor adherence to medication regimens. If individuals experience uncomfortable or undesirable side effects, they may be less likely to take their medications as prescribed or may discontinue treatment altogether. Side effects can vary from person to person. What may be tolerable for one individual may be intolerable for another. Healthcare providers must work closely with patients to find the most suitable medication and dosage.
Some individuals with ADHD who take stimulant medications may develop a tolerance over time. This means that the initial dosage that was effective may become less effective, requiring dosage adjustments or medication changes. Managing tolerance can be challenging, as healthcare providers need to strike a balance between maintaining symptom control and minimizing the risk of side effects or overmedication. Tolerance can lead to misuse or abuse of ADHD medications. Some individuals may take higher doses than prescribed to maintain the desired effects, which can have serious health consequences.
Key Market Trends
Behavioral Therapies
Behavioral therapies provide a comprehensive approach to managing ADHD symptoms. They focus on developing specific skills, strategies, and behaviors to help individuals with ADHD function more effectively in various settings, such as school, home, and work. Behavioral therapies address the core symptoms of ADHD, including inattention, impulsivity, and hyperactivity. They teach individuals how to better manage these symptoms in their daily lives. These therapies teach practical skills such as organization, time management, problem-solving, and impulse control. These skills are essential for individuals with ADHD to succeed in academics, work, and relationships. Behavioral therapies often use positive reinforcement techniques to reward desired behaviors. This can motivate individuals with ADHD to develop and maintain positive habits. Behavioral therapies often involve parents and family members, providing them with strategies to support the individual with ADHD at home and in other environments.
Behavioral interventions are tailored to the specific needs and challenges of everyone with ADHD. This individualization ensures that the therapy is effective and relevant to the person's life. Behavioral therapies can lead to long-term improvements in functioning and behavior. They equip individuals with ADHD with lifelong skills for self-management. In some cases, behavioral therapies can reduce the need for or complement the effects of medication, offering individuals and their families alternative treatment options. Behavioral interventions are often used in educational settings to support students with ADHD. These interventions can improve academic performance and classroom behavior. Learning and successfully applying behavioral strategies can boost the self-esteem and confidence of individuals with ADHD, reducing feelings of frustration and failure.
Segmental Insights
Drug Type Insights
In 2022, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market largest share was held by stimulant drug type segment and is predicted to continue expanding over the coming years.
Distribution Channel Insights
In 2022, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market largest share was held by
Online Pharmacies
Regional Insights
The North America region dominates the Global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2022.
Recent Developments
- In March 2021, KemPharm,Inc., a specialty pharmaceutical company focused on developing proprietaryprodrugs, has received approval from the U.S. Food and Drug Administration(FDA) for its New Drug Application (NDA) for AZSTARYS, previously known asKP415. This once-daily product is designed for the treatment of attentiondeficit hyperactivity disorder (ADHD) in patients aged six years and older.AZSTARYS combines serdexmethylphenidate (SDX), KemPharm's prodrug ofd-methylphenidate (d-MPH), with immediate-release d-MPH. The commercializationof AZSTARYS will be led by Corium, Inc. (Corium), a company under the portfolioof Gurnet Point Capital (GPC), as per the definitive collaboration and licenseagreement (the "License Agreement") between KemPharm and an affiliateof GPC.
- In April 2021, SupernusPharmaceuticals, Inc., a biopharmaceutical firm dedicated to developing andmarketing products targeting central nervous system (CNS) ailments, hasreceived approval from the U.S. Food and Drug Administration (FDA) for Qelbree(viloxazine extended-release capsules). This approval is specifically for thetreatment of attention-deficit hyperactivity disorder (ADHD) in pediatricpatients aged 6 to 17 years. The authorization of Qelbree is substantiated byan extensive developmental program comprising four Phase III clinical trials,involving over 1000 pediatric patients ranging from 6 to 17 years of age.
Key Market Players
- Supernus Pharmaceuticals,Inc.
- Pfizer Inc
- Novartis AG
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Hisamitsu PharmaceuticalCo., Inc.
- Chongqing Fujin BiologyMedical Company
- Purdue Pharma LP
- MallinckrodtPharmaceuticals
| By Drug Type | By Distribution Channel | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy